Enicepatide
Enicepatide (CT-388, RO7795068)
Also known as: CT-388, RO7795068
Roche's signaling-biased GLP-1/GIP dual agonist that produced 22.5% placebo-adjusted weight loss at 48 weeks in Phase 2, the strongest number in its class, with Phase 3 starting in 2026.
Overview
Enicepatide came to Roche through its acquisition of Carmot Therapeutics. It is designed to favor cAMP signaling and limit receptor internalization, which the company argues sustains the drug's effect. In the 469-patient Phase 2 reported in January 2026, the 24 mg dose gave 22.5% placebo-adjusted weight loss at 48 weeks with no plateau; about one in four participants lost 30% or more, and 73% of those with prediabetes returned to normal glucose. The Enith Phase 3 program follows in 2026.
Mechanism of action
Dual GLP-1 and GIP receptor agonism biased toward cAMP signaling with reduced beta-arrestin recruitment and receptor internalization.
Key studies & citations
- Human2026
Roche reports 48-week Phase 2 results for CT-388 in obesity
22.5% placebo-adjusted weight loss at 48 weeks on 24 mg.
Roche media release - Human2026
CT-388 Phase 2 in adults with obesity
26.1% of participants lost 30% or more of body weight.
ClinicalTrials.gov NCT06525935 - Human2026
CT-388 late-breaking abstract
73% of participants with prediabetes normalized glucose.
Diabetes (ADA 2026)
Frequently asked questions
What does 'biased agonist' mean here?
The molecule is built to trigger the receptor's cAMP signal more than the arrestin pathway that pulls receptors into the cell. The intent is a more durable effect; whether it changes outcomes versus tirzepatide is unproven.